Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; benchtop systems and rapid tests in the areas of infectious diseases; molecular point-of-care test systems for influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides blood and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:ABT
Previous Symbol
CUSIP00282410
Phone224-667-6100
Debt
Debt-to-Equity Ratio0.62
Current Ratio1.42
Quick Ratio1.13
Price-To-Earnings
Trailing P/E Ratio28.74
Forward P/E Ratio24.86
P/E Growth2.08
Sales & Book Value
Annual Sales$27.39 billion
Price / Sales4.61
Cash Flow$4.9172 per share
Price / Cash Flow14.61
Book Value$17.87 per share
Price / Book4.02
Profitability
EPS (Most Recent Fiscal Year)$2.50
Net Income$477 million
Net Margins2.91%
Return on Equity16.05%
Return on Assets6.95%
Miscellaneous
Employees99,000
Outstanding Shares1,756,330,000
Market Cap$122.86 billion
OptionableOptionable
Abbott Laboratories (NYSE:ABT) Frequently Asked Questions
What is Abbott Laboratories' stock symbol?
Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."
How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?
Abbott Laboratories announced a quarterly dividend on Thursday, September 13th. Shareholders of record on Monday, October 15th will be given a dividend of $0.28 per share on Thursday, November 15th. This represents a $1.12 dividend on an annualized basis and a yield of 1.56%. The ex-dividend date is Friday, October 12th. View Abbott Laboratories' Dividend History.
How were Abbott Laboratories' earnings last quarter?
Abbott Laboratories (NYSE:ABT) released its quarterly earnings data on Wednesday, October, 17th. The healthcare product maker reported $0.75 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.75. The healthcare product maker earned $7.66 billion during the quarter, compared to analyst estimates of $7.65 billion. Abbott Laboratories had a net margin of 2.91% and a return on equity of 16.05%. Abbott Laboratories's revenue was up 12.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.66 earnings per share. View Abbott Laboratories' Earnings History.
When is Abbott Laboratories' next earnings date?
What guidance has Abbott Laboratories issued on next quarter's earnings?
Abbott Laboratories updated its FY18 earnings guidance on Wednesday, October, 17th. The company provided EPS guidance of $2.87-2.89 for the period, compared to the Thomson Reuters consensus estimate of $2.88. Abbott Laboratories also updated its FY 2018 guidance to $2.87-2.89 EPS.
What price target have analysts set for ABT?
20 brokerages have issued 12-month target prices for Abbott Laboratories' shares. Their forecasts range from $64.00 to $86.00. On average, they anticipate Abbott Laboratories' stock price to reach $75.5842 in the next year. This suggests a possible upside of 5.2% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.
What is the consensus analysts' recommendation for Abbott Laboratories?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 4 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.
Has Abbott Laboratories been receiving favorable news coverage?
Media coverage about ABT stock has been trending positive on Wednesday, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Abbott Laboratories earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news stories about the healthcare product maker a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the near future.
Who are some of Abbott Laboratories' key competitors?
Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN).
Who are Abbott Laboratories' key executives?
Abbott Laboratories' management team includes the folowing people:
- Mr. Miles D. White, Chairman & CEO (Age 63)
- Mr. Robert B. Ford, Pres & COO (Age 44)
- Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 48)
- Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 52)
- Mr. Daniel Gesua Sive Salvadori, Exec. VP of Nutritional Products (Age 39)
Who are Abbott Laboratories' major shareholders?
Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.91%), Capital Research Global Investors (7.13%), BlackRock Inc. (6.67%), Massachusetts Financial Services Co. MA (2.20%), Bank of New York Mellon Corp (1.55%) and Morgan Stanley (1.30%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.
Which major investors are selling Abbott Laboratories stock?
ABT stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Mitsubishi UFJ Trust & Banking Corp, TIAA CREF Investment Management LLC, Marshall Wace North America L.P., Diamond Hill Capital Management Inc., Alliancebernstein L.P., Canada Pension Plan Investment Board and Bahl & Gaynor Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.
Which major investors are buying Abbott Laboratories stock?
ABT stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Capital International Investors, Matthew Goff Investment Advisor LLC, Vanguard Group Inc., Capital World Investors, Sustainable Growth Advisers LP, Morgan Stanley and Panagora Asset Management Inc.. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Daniel J Starks and Robert B Ford. View Insider Buying and Selling for Abbott Laboratories.
How do I buy shares of Abbott Laboratories?
Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abbott Laboratories' stock price today?
One share of ABT stock can currently be purchased for approximately $71.84.
How big of a company is Abbott Laboratories?
Abbott Laboratories has a market capitalization of $122.86 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.
What is Abbott Laboratories' official website?
How can I contact Abbott Laboratories?
Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.
MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
